Kooij Louise Frederika
SEC CIK 2004379 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NAMS | NewAmsterdam Pharma Co N.V. | CAO | 129.4K | — | $25.05M | 25 | 2024-09-27 | 2026-07-20 |
Most active insiders at NAMS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Davidson Michael H. | CEO, Dir | $226.5K | $25.33M |
| 2 | Kooij Louise Frederika | CAO | — | $16.75M |
| 3 | Kastelein Johannes Jacob Pieter | CSO, Dir | — | $14.26M |
| 4 | Somaiya Mayur Ian | CFO | — | $3.43M |
| 5 | LANGE LOUIS G | Dir | — | $2.19M |
| 6 | Smither John W | Dir | — | $40.5K |
| 7 | Gunning Robert William | VP, Ctrl | — | — |
| 8 | van der Kamp Hilde Johanna | Dir | — | — |
| 9 | McKenna Mark C. | Dir | — | — |
| 10 | Gulfo Adele M. | Dir | — | — |
Transactions 25
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-07-22 16:05 | 2026-07-20 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | $11.34 | +105.0K | 129.4K | +431% | +$1.19M |
| DMT | 2026-07-22 16:05 | 2026-07-20 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale+OE | $30.34 | -105.0K | 24.4K | -81% | -$3.19M |
| DMT | 2026-06-24 16:10 | 2026-06-22 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | $11.28 | +40.0K | 64.4K | +164% | +$451.0K |
| DMT | 2026-06-24 16:10 | 2026-06-22 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale+OE | $30.20 | -40.0K | 24.4K | -62% | -$1.21M |
| DMT | 2026-05-27 16:30 | 2026-05-26 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | $10.07 | +65.0K | 89.4K | +267% | +$654.5K |
| DT | 2026-05-27 16:30 | 2026-05-26 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale+OE | $35.69 | -65.0K | 24.4K | -73% | -$2.32M |
| DMT | 2026-01-29 | 2026-01-27+ | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | $10.90 | +72.4K | 64.2K | New | +$789.5K |
| DMT | 2026-01-29 | 2026-01-27+ | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale+OE | $32.25 | -72.4K | 24.4K | -75% | -$2.34M |
| DMT | 2026-01-27 | 2026-01-23+ | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | $10.90 | +72.6K | 58.8K | New | +$791.0K |
| DMT | 2026-01-27 | 2026-01-23+ | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale+OE | $33.29 | -72.6K | 24.4K | -75% | -$2.42M |
| DT | 2026-01-07 | 2026-01-07 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | A - Grant | — | +12.0K | 24.4K | +97% | — |
| DT | 2026-01-07 | 2026-01-05 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale | $33.25 | -2,647 | 12.4K | -18% | -$88.0K |
| DMT | 2025-12-29 | 2025-12-23+ | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | $10.03 | +145.0K | 41.0K | New | +$1.45M |
| DMT | 2025-12-29 | 2025-12-23+ | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale+OE | $35.84 | -145.0K | 15.0K | -91% | -$5.20M |
| DM | 2025-09-10 | 2025-09-09 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale+OE | $25.83 | -150.0K | 111.9K | -57% | -$3.87M |
| D | 2025-09-10 | 2025-09-09 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | $10.00 | +150.0K | 165.0K | +1,000% | +$1.50M |
| 2025-09-05 | 2025-09-03 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale | $25.09 | -18.1K | 15.0K | -55% | -$453.5K | |
| D | 2025-09-04 | 2025-09-02 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | — | +18.1K | 33.1K | +120% | — |
| 2025-08-27 | 2025-08-25 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale | $24.86 | -8,269 | 15.0K | -36% | -$205.6K | |
| D | 2025-03-28 | 2025-03-26 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | $0.00 | +8,269 | 23.3K | +55% | $0 |
| D | 2025-03-05 | 2025-03-04 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | — | +150.0K | 165.0K | +1,000% | — |
| D | 2025-03-05 | 2025-03-04 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale+OE | $20.37 | -150.0K | 15.0K | -91% | -$3.06M |
| 2025-01-07 | 2025-01-07 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | A - Grant | — | +15.0K | 15.0K | New | — | |
| D | 2024-10-01 | 2024-09-27 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | M - OptEx | — | +45.0K | 45.0K | New | — |
| D | 2024-10-01 | 2024-10-01 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | CAO | S - Sale+OE | $15.72 | -45.0K | 0 | -100% | -$707.4K |
Purchase Sale Sale after option exercise All abbreviations